Creative Medical Technology (CELZ) vs Senti Biosciences (SNTI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Senti Biosciences is the larger company by market cap ($10.0 million vs $6.2 million), about 1.6 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CELZ | SNTI |
|---|---|---|
| Share price | $0.82 | $0.3216 |
| Market cap | $6.23M | $10.02M |
| 1-day change | -4.68% | -0.03% |
| YTD return | — | -69.07% |
| 1-year return | — | -81.93% |
| 5-year return | — | -99.68% |
| EPS (TTM) | $-2.07 | $-1.72 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.25 | $2.88 |
| 52-week low | $0.62 | $0.29 |
| Distance from 52-week high | -86.88% | -88.83% |
| Analyst consensus | none | none |
| Avg. price target upside | +2339.02% | +4097.76% |
| Average volume | 6.77M | 573.78K |
| Shares outstanding | 7.59M | 31.15M |
| Employees | 4 | 39 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Creative Medical Technology
CELZ stock →Creative Medical Technology Holdings, Inc., a commercial-stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction, and FemCelz for the treatment of loss of genital sensitivity and dryness.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 4 employees
About Senti Biosciences
SNTI stock →Senti Biosciences Holdings, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The company's lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications with unmet need.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 39 employees
CELZ vs SNTI FAQ
Which is bigger, Creative Medical Technology or Senti Biosciences?
Senti Biosciences (SNTI) is larger, with a market capitalization of $10.02M compared with $6.23M for Creative Medical Technology (CELZ).
Are Creative Medical Technology and Senti Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.